BRPI1015006A2 - uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas - Google Patents

uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas

Info

Publication number
BRPI1015006A2
BRPI1015006A2 BRPI1015006A BRPI1015006A BRPI1015006A2 BR PI1015006 A2 BRPI1015006 A2 BR PI1015006A2 BR PI1015006 A BRPI1015006 A BR PI1015006A BR PI1015006 A BRPI1015006 A BR PI1015006A BR PI1015006 A2 BRPI1015006 A2 BR PI1015006A2
Authority
BR
Brazil
Prior art keywords
periocular
tocotrienols
topical
treatment
ophthalmic diseases
Prior art date
Application number
BRPI1015006A
Other languages
English (en)
Portuguese (pt)
Inventor
M Miller Guy
Kheifets Viktoria
D Shrader William
Original Assignee
Ampere Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampere Life Sciences Inc filed Critical Ampere Life Sciences Inc
Publication of BRPI1015006A2 publication Critical patent/BRPI1015006A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1015006A 2009-04-28 2010-04-27 uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas BRPI1015006A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21476009P 2009-04-28 2009-04-28
PCT/US2010/032622 WO2010126910A1 (en) 2009-04-28 2010-04-27 Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases

Publications (1)

Publication Number Publication Date
BRPI1015006A2 true BRPI1015006A2 (pt) 2019-09-24

Family

ID=43032521

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015006A BRPI1015006A2 (pt) 2009-04-28 2010-04-27 uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas

Country Status (6)

Country Link
US (1) US20120136048A1 (enExample)
EP (1) EP2424360A4 (enExample)
JP (1) JP2012525398A (enExample)
BR (1) BRPI1015006A2 (enExample)
CA (1) CA2760357A1 (enExample)
WO (1) WO2010126910A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583084C (en) 2003-09-19 2010-12-07 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
EP2564842A1 (en) * 2005-06-01 2013-03-06 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
CA2704473C (en) 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2974482C (en) 2008-10-28 2019-10-29 Bioelectron Technology Corporation High purity alpha tocotrienol quinone and processes for preparing same
NO2424495T3 (enExample) 2009-04-28 2018-06-16
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
WO2012158018A2 (en) * 2011-05-18 2012-11-22 Malaysian Palm Oil Board Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to angiogenesis and method of preparation thereof
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
CN114702406B (zh) 2014-12-16 2025-02-25 Ptc医疗公司 化合物的多晶型和无定形形式
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2018136871A1 (en) * 2017-01-20 2018-07-26 Ohio State Innovation Foundation Topical tocotrienol compositions and methods of increasing skin stem cells
MY210324A (en) 2018-10-17 2025-09-11 Ptc Therapeutics Inc 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
EP3981397A1 (en) * 2020-10-08 2022-04-13 Global Scientific Tocotrienols derivates, methods and uses thereof
MX2024000445A (es) 2021-07-08 2024-04-05 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
JPH09157165A (ja) * 1995-12-11 1997-06-17 Lion Corp 点眼薬及び白内障の遅延・治療用剤
JPH10109934A (ja) * 1996-10-04 1998-04-28 Sekisui Chem Co Ltd 炎症性眼疾患用剤
JP4447198B2 (ja) * 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20040034093A1 (en) * 2002-05-30 2004-02-19 Hensley Kenneth L. Methods for enhancing motor performance and/or endurance
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
CA2583084C (en) * 2003-09-19 2010-12-07 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
ES2532997T3 (es) * 2005-04-22 2015-04-06 Elizabeth Stuart Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia
US20070092502A1 (en) * 2005-09-01 2007-04-26 Allergan, Inc. Method of Treating Glaucoma
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
JP5731980B2 (ja) * 2008-10-09 2015-06-10 ラムズコア， インコーポレイテッド ドライアイ症候群の処置のための組成物および方法

Also Published As

Publication number Publication date
WO2010126910A1 (en) 2010-11-04
EP2424360A1 (en) 2012-03-07
US20120136048A1 (en) 2012-05-31
EP2424360A4 (en) 2012-10-03
JP2012525398A (ja) 2012-10-22
CA2760357A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
BRPI1015006A2 (pt) uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
LTPA2019519I1 (lt) Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
BRPI1013377A2 (pt) formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
DK2483255T3 (da) Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
PT2898885T (pt) Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
PT2838539T (pt) Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
BR112014030406A2 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.